Abstract
Introduction
Numbers tell the story in psychiatric disease drug development: almost 300
recognized indications, 28% 12-month prevalence that yields large patient
populations, strong 7.5% annual sales growth in recent years, sustained
franchise sales, tolerance for use of multiple drugs within a drug class, and
a clinical pipeline of more than 150 agents. Given the heterogeneity of the
patient populations in the psychiatric disease sector, unmet need and
commercial opportunity are high. We explore ways in which companies are using
strategic differentiation and novel targets to overcome challenges and tap
sales potential.
Questions Answered in This Report
- A database search of agents in development for psychiatric disease yields
nearly 300 agents. From this list, we have confi rmed that more than 150 of
the agents are still in clinical development for psychiatric diseases. What
are the most common indication and mechanism targets of development? How
advanced is the pipeline overall? What companies are most active in
psychiatric drug development?
- Unmet needs create opportunities for emerging agents. What are the
unmet needs specifi c to psychiatric indications? Are there any drugs in the
pipeline that promise to address these unmet needs?
- Eli Lilly leads the psychiatric sector in terms of sales; GlaxoSmithKline
(GSK), another sales leader, stands out with the largest pipeline; and
AstraZeneca (AZ) is notable for being a sales leader with just one marketed
psychiatric disease agent. What accounts for the success of these companies
to date? How are they defending their leadership positions? What other
companies are vying for prime positions in this sector?
- With many drugs on the market and many of them available g enerically,
competition is intense in this marketplace. What strategies have companies
used to preserve patient share and market share? How are makers of emerging
agents likely to position their products?
Scope
- 2008 market: 2008 sales; leading drug classes; market-leading
companies; commercial position of leading agents.
- Psychiatric disease pipeline: number of agents in development;
disease focus; active companies; profi les of GSK and AZ; mechanisms of
action; company type; phase analysis; novel formulations versus reformulations.
- Psychiatric diseases focused on in this report: schizophrenia;
depression; anxiety; addiction; attention-defi cit/hyperactivity disorder
(ADHD); cognitive impairment associated with schizophrenia (CIAS).
- Opportunities in psychiatric diseases: unmet needs of current
treatments; treatmentresistant depression; bipolar depression; CIAS; line
extensions.
- Challenges in psychiatric diseases: availability of generics; PCP
versus specialist prescribing; reimbursement issues.
Mentioned in This Report
- Addiction
- Attention-defi cit hyperactivity disorder
- Bipolar disorder
- Generalized anxiety disorder
- Major depressive disorder
- Panic disorder
- Schizophrenia
- Social anxiety disorder
| 
View Cart
